Daily Archives: September 11, 2022
Practical Recommendations | How to deal with sleep problems during heat waves.
11 Sep, 2022 | 23:00h | UTCCommentary: How to sleep in a heat wave, according to experts – CNN
RCT | In patients with severe burns, supplemental glutamine did not improve outcomes.
11 Sep, 2022 | 22:59h | UTCA Randomized Trial of Enteral Glutamine for Treatment of Burn Injuries – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
RE-ENERGIZE Study: In this trial involving critically ill patients with burn injuries, enteral glutamine supplementation did not reduce the time to discharge alive from the hospital. @DarenHeyland #europeanburnsassociation #eba #burns https://t.co/f69MDVmsNv pic.twitter.com/fMWr675aCJ
— NEJM (@NEJM) September 9, 2022
RCT | In youths with new-onset type 1 diabetes, intensive glucose control for 24 months with a closed-loop system did not help to preserve pancreatic function.
11 Sep, 2022 | 22:57h | UTCClosed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Preservation of C-Peptide Secretion Examined in Youth With T1D – HealthDay
Commentary on Twitter (video summary)
In patients with newly diagnosed type 1 diabetes, it is uncertain whether intensive glucose control can prevent the decline in endogenous insulin secretion. New research findings are summarized in a short video. https://t.co/gJeYus4G5z pic.twitter.com/igclSnyanu
— NEJM (@NEJM) September 10, 2022
Two large clinical trials showed Vitamin D supplements do not reduce the risk of Covid-19.
11 Sep, 2022 | 22:56h | UTCEditorial: Can vitamin D protect against covid-19? – The BMJ
News Release: No link between vitamin D supplements and reduced risk of covid-19 – BMJ Newsroom
Cohort study showed a possible link between artificial sweeteners and heart disease.
11 Sep, 2022 | 22:55h | UTCNews Release: Possible link between artificial sweeteners and heart disease – BMJ Newsroom
Original Study: Artificial sweeteners and risk of cardiovascular diseases: results from the prospective NutriNet-Santé cohort – The BMJ
Monkeypox: disease epidemiology, host immunity and clinical interventions.
11 Sep, 2022 | 22:54h | UTC
Commentary on Twitter
Monkeypox: disease epidemiology, host immunity and clinical interventions https://t.co/dmu06NZoPt pic.twitter.com/vZqbxp7Wzn
— Nature Rev Immunol (@NatRevImmunol) September 8, 2022
Extracorporeal membrane oxygenation during respiratory pandemics: past, present, and future.
11 Sep, 2022 | 22:53h | UTC
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma.
11 Sep, 2022 | 22:50h | UTCAASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma – Hepatology
Guideline | Perioperative care of patients undergoing major complex spinal instrumentation surgery.
11 Sep, 2022 | 22:49h | UTC
RCT | Rezvilutamide vs. Bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer.
11 Sep, 2022 | 22:52h | UTCCommentaries:
Treatment options for metastatic hormone-sensitive prostate cancer – The Lancet Oncology
Rezvilutamide benefits shown in metastatic hormone-sensitive prostate cancer – medwire News
Commentary on Twitter
In a preplanned interim analysis of the phase III CHART trial in pts with high-volume mHSPC, rezvilutamide +ADT improve PFS (HR 0.44, 95% CI 0.33–0·.8; P<0.0001) & OS (HR 0.58, 95% CI 0.44–0.77]; P=0.0001) compared with bicalutamide + ADT: https://t.co/42IVnDUxfH #PCSM #uroonc
— NatureRevClinOncol (@NatRevClinOncol) September 7, 2022
Guidelines for cancer treatment during pregnancy: ethics-related content evolution and implications for clinicians.
11 Sep, 2022 | 22:47h | UTC
Five-year outcomes in patients with fully magnetically levitated vs. axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial.
11 Sep, 2022 | 22:43h | UTCFive-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial – JAMA (free for a limited period)
Commentary on Twitter
Among patients with advanced #heartfailure, receipt of a fully magnetically levitated centrifugal-flow LVAD vs axial-flow LVAD was associated with a better composite outcome and higher likelihood of overall survival at 5 years. #Research https://t.co/S0KdHp0tAO
— JAMA (@JAMA_current) September 8, 2022
A randomized crossover trial with 12 patients showed that a bihormonal “artificial pancreas” with closed-loop glucose control increases patients’ time on euglycemia after total pancreatectomy.
11 Sep, 2022 | 22:45h | UTCBihormonal Artificial Pancreas With Closed-Loop Glucose Control vs Current Diabetes Care After Total Pancreatectomy: A Randomized Clinical Trial – JAMA Surgery (free for a limited period)
Commentary: Novel Bihormonal Artificial Pancreas Beneficial After Pancreatectomy – HealthDay
Survey | Medical counseling on sexual enrichment aids: women’s preferences and medical practitioner expertise.
11 Sep, 2022 | 22:42h | UTC
Screening for high-risk human papillomavirus using passive, self-collected menstrual blood.
11 Sep, 2022 | 22:41h | UTCCommentary: Pap smears, be gone? Using menstrual blood to detect HPV – Stanford Medicine
Commentary on Twitter
FREE: Screening for High-Risk Human Papillomavirus Using Passive, Self-Collected Menstrual Blood #obgyn #HPV #GYN https://t.co/zLno2ab605 pic.twitter.com/mfPGjlTLdD
— The Green Journal (@greenjrnl) September 1, 2022
Network M-A | Comparative efficacy of lipid‐lowering therapies added to maximally tolerated statins for the reduction of LDL cholesterol.
11 Sep, 2022 | 22:38h | UTC
Study shows vaginal birth is feasible in some patients with low-lying placenta.
11 Sep, 2022 | 22:39h | UTCCommentary: Vaginal birth possible in 50% of women with low-lying placenta – MDedge
RCT | Effects of Nicorandil administration on infarct size in patients with ST‐Segment–Elevation Myocardial Infarction undergoing primary percutaneous coronary intervention.
11 Sep, 2022 | 22:37h | UTC
Nonadherence was revealed through measurements of serum concentrations of antihypertensive drugs in one-third of patients with resistant hypertension previously evaluated as adherent.
11 Sep, 2022 | 22:35h | UTC
M-A | Performance of single serum progesterone in the evaluation of symptomatic first-trimester pregnant patients.
11 Sep, 2022 | 22:32h | UTCPerformance of single serum progesterone in the evaluation of symptomatic first-trimester pregnant patients: a systematic review and meta-analysis – Canadian Journal of Emergency Medicine (if the link is paywalled, try this one)
M-A | Combination therapy with rifaximin and lactulose in hepatic encephalopathy.
11 Sep, 2022 | 22:33h | UTCCommentary: Rifaximin Plus Lactulose Linked to Greater Effectiveness, Decreased Mortality in HE – AJMC
Systematic Review | Long-term outcomes after non-traumatic out-of-hospital cardiac arrest in pediatric patients.
11 Sep, 2022 | 22:30h | UTC
Systematic Review | Surgery for the treatment of obesity in children and adolescents.
11 Sep, 2022 | 22:29h | UTCSurgery for the treatment of obesity in children and adolescents – Cochrane Library
Summary: Surgery for the treatment of obesity in children and adolescents – Cochrane Library
RCT | Adjuvant atezolizumab fails to improve outcomes in patients with renal cell carcinoma at increased risk of recurrence following resection.
11 Sep, 2022 | 22:28h | UTCAdjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentaries:
Adjuvant atezolizumab falls short in renal cell carcinoma – Urology Times
IMmotion010 does not support adjuvant atezolizumab in intermediate-, high-risk RCC – medwire News
Commentary from the author on Twitter (thread – click for more)
Grateful to @TheLancet for allowing us to publish our experience with #adjuvant #atezolizumab (#IMmotion010) simultaneous w the presentation by #AxelBex at #ESMO22. It's interesting to envision how this data impacts current landscape (link below): (1/10) https://t.co/F5Y5HyNaxY pic.twitter.com/klAYWAQVwV
— Sumanta Pal (@montypal) September 10, 2022
Phase 2 RCT | Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease.
11 Sep, 2022 | 22:25h | UTC